Search Results
Nov 10, 2025, 09:48 ET Bracco Shapes the Future of Radiology at RSNA 2025 Annual Meeting
UseAiMIFY is an image processing software that can be used for image enhancement in MRI images. It can be used to increase contrast-to-noise ratio (CNR), contrast enhancement (CEP), and lesion-to-brain ratio (LBR) of enhancing tissue in brain MRI images acquired with a gadolinium-based contrast agent.
More news about: Bracco Group
Nov 06, 2025, 06:45 ET Core Natural Resources Reports Third Quarter 2025 Results
CANONSBURG, Pa., Nov. 6, 2025 /PRNewswire/ -- Today, Core Natural Resources, Inc. (NYSE: CNR) ("Core" or the "company") reported net income of $31.6 million, or $0.61 per diluted share, in the third quarter of 2025. Additionally, Core reported
More news about: Core Natural Resources
Nov 03, 2025, 07:32 ET B. Riley Securities to Host 5th Annual Convergence Conference: AI, Blockchain & Energy in New York on December 4 2025
Bitdeer Technologies Group (BTDR) Blink Charging Co. (BLNK) Core Natural Resources, Inc. (CNR) enCore Energy Corp. (EU) Energy Fuels, Inc. (UUUU) FuelCell Energy,
More news about: B. Riley Securities
Oct 23, 2025, 07:55 ET Core Natural Resources to Announce Third Quarter 2025 Results on November 6
CANONSBURG, Pa., Oct. 23, 2025 /PRNewswire/ -- Core Natural Resources, Inc. (NYSE: CNR) will discuss its third quarter 2025 financial results on an investor conference call on Thursday, November 6, 2025 at 11:00 a.m. Eastern time.
More news about: Core Natural Resources
Oct 08, 2025, 07:55 ET Core Natural Resources Announces Leadership Change
CANONSBURG, Pa., Oct. 8, 2025 /PRNewswire/ -- Today, Core Natural Resources, Inc. (NYSE: CNR) ("Core," the "company," "we" or "our") announced that its board of directors has appointed Core's board chair, Jimmy Brock, to the additional role of
More news about: Core Natural Resources
Sep 24, 2025, 09:00 ET SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials
oncology company advancing its innovative nanotechnology-enabled cancer drug, today announced the successful close of its Convertible Note Round #3 (CNR 3) at $5.5 million. The round, which officially closed on September 5, 2025,
More news about: SciTech Development, Inc.